Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
Such models learn on a large collection of molecular structures and produce novel compounds. In this work, we introduce Molecular Sets (MOSES), a benchmarking platform to support research on machine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback